Saakshi Khattri, MD: Evaluating the Newest Data in CLE

Dr. Khattri looks at the 52-week findings from the ongoing phase 2/3 AMETHYST trial evaluating litifilimab in cutaneous lupus erythematosus (CLE), which were presented at the EADV Congress 2026. She notes that there are currently no FDA-approved targeted therapies for CLE, a disease that can cause permanent scarring, dyspigmentation, and scarring alopecia. Litifilimab, a monoclonal antibody that targets BDCA2, demonstrated continued improvement through 52 weeks rather than plateauing, according to Dr. Khattri. She emphasizes the importance of durability of treatment for patients with CLE who have had an inadequate response to first-line therapy.